AiCure

United States

Janssen Labs expands to San Francisco, adds three to @LabCentral

Thursday, May 15, 2014 01:26 PM

Janssen Labs, part of Janssen R&D, plans to open Janssen Labs @South San Francisco, a new 30,000-square-foot, standalone operation based in South San Francisco, Calif. The new location will accommodate up to 50 independent, emerging companies to be co-located with staff from Johnson & Johnson Innovation. Like the flagship Janssen Labs in San Diego, Janssen Labs @South San Francisco will include a combination of shared and private lab and office spaces and feature value-added solutions including operational support, education and business services. Janssen Labs @South San Francisco is scheduled to open at the end of the year.

More... »


Pernix to acquire Treximet migraine tablets from GlaxoSmithKline

Thursday, May 15, 2014 11:23 AM

Pernix Therapeutics, a specialty pharmaceutical company, has signed an agreement with GlaxoSmithKline to acquire the U.S. rights to Treximet (sumatriptan / naproxen sodium) for the acute treatment of migraine attacks with or without aura in adults.

More... »


Kinex Pharmaceuticals appoints two to New Jersey clinical office

Wednesday, May 14, 2014 03:22 PM

Kinex Pharmaceuticals has announced the addition of two key executives to its clinical leadership team reporting to chief medical officer, Dr. Rudolf Kwan. Douglas Kramer, M.D., joins Kinex as vice president of Clinical and Regulatory Affairs and Jane Devane has joined Kinex as director of Clinical Operations.

More... »

Abeona Therapeutics receives FDA Orphan Drug Designations for Sanfilippo

Wednesday, May 14, 2014 02:54 PM

Abeona Therapeutics, a start-up company created around intellectual property licensed from Nationwide Children's Hospital to develop treatments for Sanfilippo Syndrome Types A and B, has been granted Orphan Drug Designations for its lead investigational therapies by the FDA Office of Orphan Products Development. Following the successful close of seed financing in late 2013, Abeona is raising funds to advance its gene therapy-based clinical programs for both Sanfilippo Syndrome type A and B. Phase I/II clinical trials for both diseases are anticipated to begin in 2014.

More... »

UCLA receives $4 million from Eli and Edythe Broad Foundation

Wednesday, May 14, 2014 01:05 PM

Two new gifts from the Eli and Edythe Broad Foundation to UCLA totaling $4 million will fund research in stem cell science and digestive diseases and support the recruitment of key faculty at two research centers.

More... »

FDA approves Bayer's Kogenate FS Antihemophilic Factor VIII (recombinant)

Monday, May 12, 2014 12:35 PM

The FDA has approved a new indication for Bayer's Kogenate FS antihemophilic factor VIII (recombinant) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults with hemophilia A. The approval is based on data from the SPINART study, in which 84 patients ages 15 to 50 were randomized to either prophylaxis (25IU/kg three times per week) or on-demand treatment.

More... »

FDA approves Zontivity to reduce risk of heart attacks and stroke

Friday, May 9, 2014 12:50 PM

The FDA has approved Zontivity (vorapaxar) tablets to reduce the risk of heart attack, stroke, cardiovascular death and need for procedures to restore the blood flow to the heart in patients with a previous heart attack or blockages in the arteries to the legs.

More... »

Moffitt Cancer Center, Vermillion collaborate

Friday, May 9, 2014 12:32 PM

The Moffitt Cancer Center in Tampa, Fla., and Austin-based Vermillion have announced a research collaboration, launching a study to produce clinical and economic data to support a new value-based practice model that may improve survival, quality of life and cost-effectiveness of care for patients with ovarian cancer.

More... »

FDA approves EPANOVA for severe hypertriglyceridemia

Wednesday, May 7, 2014 02:43 PM

AstraZeneca has announced the FDA approved EPANOVA (omega-3-carboxylic acids) as an adjunct to diet to reduce triglyceride levels in adults with severe hypertriglyceridemia (triglyceride levels greater than or equal to 500mg/dL).

More... »

ACRP CCRC designation recognized by American Nurses Credentialing Center

Wednesday, May 7, 2014 01:34 PM

The Association of Clinical Research Professionals' (ACRP) Certified Clinical Research Coordinator (CCRC) designation now is recognized by the American Nurses Credentialing Center (ANCC) as a valid designation toward meeting staffing requirements of the ANCC Magnet Recognition Program.

More... »

`
CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

November 24

Tufts CSDD’s $2.6 billion price tag to develop and bring a new drug to market raises questions, criticisms

Medidata joins GlaxoSmithKline in study to evaluate the impact of wearing mobile devices in clinical trials

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

October

CROs driving changes in patient recruitment
Data- and tech-aided enrollment services a competitive advantage

Trials with in-home nurses poised to grow
Higher expense, but may improve recruitment and retention for select trials

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs